ORIGINAL ARTICLE

Presence of the p.L456V polymorphism in Cuban patients clinically diagnosed with Wilson’s disease☆,☆☆

Y. Clark-Feoktistova a,*, C. Ruenes-Domech b, E.F. García-Bacallao c, H. Roblejo-Balbuena d, L. Feoktistova e, I. Clark-Feoktistova f, O. Jay-Herrera g, T. Collazo-Mesa h

a Máster en Ciencias Biológicas, Universidad de Guantánamo (UG). Laboratorio de Biología Molecular, Guantánamo, Cuba
b Especialista de primer grado en Gastroenterología, Directora del Instituto Nacional de Gastroenterología (ING), La Habana, Guantánamo, Cuba
c Especialista de primer grado en Gastroenterología, Subdirectora de Docencia del Instituto Nacional de Gastroenterología (ING), La Habana, Guantánamo, Cuba
d Especialista de primer grado de Genética Clínica, Centro Nacional de Genética Médica, La Habana, Guantánamo, Cuba
e Especialista en Lenguas Extranjeras, Universidad de Guantánamo, Guantánamo, Cuba
f Especialista en Química, CITMA, Guantánamo, Cuba
g Especialista en Bioestadística, Universidad de Guantánamo (UG), Guantánamo, Cuba
h Laboratorio de Biología Molecular, Centro Nacional de Genética Médica, La Habana, Guantánamo, Cuba

Received 4 December 2017; accepted 18 March 2018
Available online 19 September 2018

KEYWORDS
Wilson’s disease; p.L456V polymorphism; Single-strand conformation polymorphism

Abstract
Introduction and aims: Wilson’s disease is characterized by the accumulation of copper in different organs, mainly affecting the liver, brain, and cornea, and is caused by mutations in the ATP7B gene. More than 120 polymorphisms in the ATP7B gene have been reported in the medical literature. The aim of the present study was to identify the conformational changes in the exon 3 region of the ATP7B gene and detect the p.L456V polymorphism in Cuban patients clinically diagnosed with Wilson’s disease.


☆ The present study is the result of the joint work of the Centro Nacional de Genética Médica (a center collaborating with the WHO for the development of genetic approaches to health promotion), the Instituto Nacional de Gastroenterología, and the Universidad de Guantánamo.

* Corresponding author. Calle 2, Edificio 23, apartamento 143C. Reparto Obrero. Guantánamo, Cuba. Tel.: +5-3461444.
E-mail address: feoktistova@cug.co.cu (Y. Clark-Feoktistova).

2255-534X/© 2018 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Wilson’s disease (WND: MIM# 27790) presents with an autosomal recessive inheritance pattern and is a worldwide health problem. It is classified as a rare genetic disease for which there is treatment, and if untreated, it can cause irreversible damage to the liver and brain that lead to the death of the patient.

The disorder is characterized by an accumulation of copper in different organs: the liver, brain, and cornea. Its clinical diagnosis is complex. A distinctive feature of the disease is liver damage, which can manifest through elevated serum transaminase levels to fulminating hepatitis. Patients with WND can suffer alterations at the level of the brain, and can present with psychiatric disorders, such as depression and suicidal tendencies, among others.
The molecular cause of WND are mutations in the ATP7B gene. Said gene has 20 introns and 21 exons that encode for the ATP7B protein, which is the copper transporter in the hepatocyte. More than 120 polymorphisms have been identified that are distributed in the entire ATP7B gene and in the introns. The most polymorphic exons reported are: 2, 8, and 16.1

The p.L456 V polymorphism is located in the exon 3 region of the ATP7B gene and is identified in different populations, such as those in China,2 Taiwan,3 Egypt,4 and Venezuela,5 among others. A single nucleotide polymorphism (SNP), it is used in the determination of haplotypes in families with patients that have WND, making their molecular diagnosis possible.6

Adequate screening technology is required to establish the spectrum of polymorphisms in the ATP7B gene. One of the most widely used techniques for that purpose is the single-strand conformational polymorphism (SSCP) analysis. It is based on the relation between the electrophoretic mobility of single-stranded DNA and its three-dimensional structure. A change in the DNA sequence causes a conformational change that in turn causes a change in mobility in the electrophoresis that is detectable by that technique. Thus, conformational changes that are different from the normal variant can be identified in the DNA samples.7

Aims

The aim of the present study was to identify the conformational changes in the exon 3 region and detect the p.L456 V polymorphism in Cuban patients with presumptive WND diagnosis.

Materials and methods

A descriptive study was carried out at the Centro Nacional de Genética Médica, within the time frame of 2007-2012, that included 105 patients (43 women and 62 men) with the presumptive diagnosis of WND seen at the Instituto Nacional de Gastroenterología. All the patients consented to participate in the study in accordance with the ethical principles of the Declaration of Helsinki.

The variables analyzed were: allelic frequency of the p.L456 V polymorphism, conformational change a for the normal variant, conformational change b for the presence of p.L456 V polymorphism in the heterozygous state, and conformational change c for its presence in the homozygous state. The clinical manifestations were classified as hepatic, neurologic, and psychiatric, as well as their combinations.

The clinical manifestations were evaluated by a multidisciplinary team (gastroenterologists, geneticists, neurologists, and biochemists). The established diagnostic criteria for the disease were followed.

The exon 3 region of the ATP7B gene was selected to detect the conformational changes and identification of the p.L456 V polymorphism. Blood was drawn from all the patients and DNA extracted through the salting-out method8 from 10 ml of peripheral blood with ethylenediaminetetraacetic acid (EDTA) 56 mg/ml. The conditions for amplifying exon 3 through the polymerase chain reaction (PCR) were: 100 ng of DNA, 10(F) 5'-AGT CGC CAT GTA AGT GAT AA-3' and (R) 5'-CTG AGG GAA CAT GAA ACA A-3', 1 mM of dNTPs (Boehringer), 10X PCR buffer, 15 mM of MgCl2, 0.3 U of Taq polymerase (Invitrogen), in a volume of 25 µl.

SSCP electrophoresis was then performed, mixing 3.5 µl with a stop solution of blue bromophenol (0.05% BFA, 10 mM NaOH, 95% formamide, 20 mM EDTA), and 1 µl of the amplified product in a final volume of 7 µl, and applied in a gel of commercial acrylamide (GeneGel Excel 12, 5/24 Kit). DNA was visualized through the silver staining method, following the instructions of the commercial PlusOne DNA Silver Staining kit (Amersham Biosciences, 2007).

The controls utilized (DNA samples from patients that were heterozygous and homozygous for the p.L456 V polymorphism) were donated by Georgios Loudianos, a researcher at the Ospedale Regionale per le Microcitemie laboratory (Cagliari, Italy).

The frequency comparisons were analyzed using the chi-square test.

The present study was approved by the scientific council and the ethics committee of the Centro Nacional de Genética Médica and the Instituto Nacional de Gastroenterología.

Results

The mean age of the 105 patients that presented with the p.L456 V polymorphism was 31.6 ± 14.1 and the range was 11 years (minimum) and 58 years (maximum).

The study patients with the p.L456 V polymorphism came from 10 provinces and the special municipality of Isla de la Juventud. The most widely represented province was La Habana, followed by Pinar del Río (fig. 1).

The so-called b and c conformational changes were identified through the SSCP technique (fig. 2) and the so-called a conformational change corresponded to the normal variant. The b and c conformational changes corresponded to the presence of the heterozygous state and the homozygous state of the p.L456 V polymorphism, respectively.

The b conformational change was detected in 42 patients (40%), 22 patients (21%) had the c conformational change, and the a conformational change was detected in 41 patients.

---

**Figure 1** PR: Pinar del Río, IJ: Isla de la Juventud, Hab: Habana, Cienf: Cienfuegos, VC: Villa Clara, SS: Santi Spiritus, Cam: Camagüey, Stgo: Santiago de Cuba, Gtmo: Guantánamo.
Of the 105 Cuban patients with the presumptive clinical diagnosis of Wilson’s disease, 42 were determined through the SSCP technique as heterozygous for the p.L456 V polymorphism and 22 were homozygous. The allelic frequency of the p.L456 V polymorphism of the Cuban patients studied in the present analysis was 41%.

The p.L456 V polymorphism is the consequence of the change of guanine for cytosine, causing the amino acid, leucine, to be changed for valine at position 456 of the ATP7B protein. That change does not affect the function of ATP7B, the copper-transporting protein, in humans, and it has been detected in different populations with a frequency above 1%.1–3

The most frequent clinical manifestations in our study patients that presented with the p.L456 V polymorphism were hepatic symptoms (78%), neurologic symptoms (9%), and mixed symptoms (neurologic and psychiatric) (2%) (Table 1).

The presence of Kayser-Fleischer rings, a diagnostic criterion for Wilson’s disease, was identified in four patients with the p.L456 V polymorphism, representing 6.3% of the study patients. The clinical manifestations of those four patients were: two with hepatic and neurologic symptoms, one with neurologic symptoms, and one with neurologic and psychiatric symptoms.

**Discussion and conclusions**

The age of our study patients with the p.L456 V polymorphism was similar to that reported in the international literature.

In the distribution by province, La Habana and Pinar de Rio had the highest number of patients with the p.L456 V polymorphism. The majority of patients with that polymorphism are concentrated in the Western region of the country.

More than 120 polymorphisms in the ATP7B gene have been reported in patients with Wilson’s disease. In Cuba, detection of the p.L456 V polymorphism began in 2007 at the Centro Nacional de Genética Médica. The step before the search for mutations and polymorphisms in the ATP7B gene is the detection of the conformational changes utilizing the SSCP technique. The p.L456 V polymorphism was determined by the SSCP comparison of the electrophoretic runs of the positive heterozygous and homozygous controls of the p.L456 V polymorphism with the PCR product obtained from the exon 3 region of the ATP7B gene from the samples of the Cuban patients analyzed.

The frequency of the p.L456 V polymorphism in two Chinese studies was similar to that of our analysis (there were no statistically significant differences), and as expected, frequency was above 1%. There were statistically significant different when our results were compared with those conducted in Egypt, India, Iran, and Taiwan. A possible explanation for that is the ethnic origin of the Cuban population. As shown in Table 2, our result is the second highest in frequency of those reported in the countries analyzed. Future studies will evaluate the impact of the p.L456 V polymorphism in Cuban patients with a molecular diagnosis of WND. It was interesting to observe that the frequency of the p.L456 V polymorphism was very low in India (1.8%), where it is as a rare variant.

---

**Table 1**  Main clinical manifestations in Cuban patients presenting with the p.L456 V polymorphism.

<table>
<thead>
<tr>
<th>L456V polymorphism</th>
<th>H</th>
<th>N</th>
<th>H and N</th>
<th>N and P</th>
</tr>
</thead>
<tbody>
<tr>
<td>H: hepatic manifestations; N: neurologic manifestations, H and N: hepatic and neurologic manifestations; N and P: neurologic and psychiatric manifestations.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 2** Single-stand conformation polymorphism (SSCP) of exon 3 of the ATP7B gene in two positive controls for the p.L456 V polymorphism visualized in an acrylamide gel at 12.5%. The ladders correspond to: 1: conformational change a, normal variant, negative control; 2: conformational change b, heterozygous control for the p.L456 V polymorphism (C-1); 3: conformational change c, homozygous control for the p.L456 V polymorphism (C-2); 4: conformational change c, homozygous for the p.L456 V polymorphism; 5: conformational change b, heterozygous for the p.L456 V polymorphism.

---

**Figure 3** Frequency of the conformational changes in exon 3 in percentages. The so-called b and c conformational changes are heterozygous patients and homozygous patients for the p.L456 V polymorphism, respectively.


Table 2  Frequencies by country of the p.L456 V polymorphism in patients with the clinical diagnosis of Wilson’s disease.

<table>
<thead>
<tr>
<th>Countries</th>
<th>Frequency</th>
<th>References</th>
<th>Probability</th>
<th>Standard error</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cuba</td>
<td>41%</td>
<td></td>
<td>p &lt; 0.001</td>
<td>4.7</td>
</tr>
<tr>
<td>Egypt</td>
<td>12.5%</td>
<td>5</td>
<td></td>
<td>4.7</td>
</tr>
<tr>
<td>China</td>
<td>42%</td>
<td>9 NS</td>
<td></td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>49.3%</td>
<td>3 NS</td>
<td></td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>64%</td>
<td>12 p &lt; 0.001</td>
<td></td>
<td>4.7</td>
</tr>
<tr>
<td>India</td>
<td>1.8%</td>
<td>10</td>
<td>p &lt; 0.001</td>
<td>4.7</td>
</tr>
<tr>
<td>Iran</td>
<td>23%</td>
<td>11</td>
<td>p &lt; 0.001</td>
<td>4.7</td>
</tr>
<tr>
<td>Taiwan</td>
<td>25%</td>
<td>4</td>
<td>p &lt; 0.001</td>
<td>4.7</td>
</tr>
</tbody>
</table>

Studies have been conducted in several countries that carried out molecular analyses in patients with WDN, but they did not report the presence of the p.L456 V polymorphism. In Turkey, the p.L456 V variant was not identified, but the p.V446L polymorphism was found in the exon 3 region (where the p.L456 V polymorphism is located). Advanced technology is required for successfully achieving the molecular diagnosis of genetic diseases that possess one or more genes with an elevated number of exons. Different molecular studies have been conducted on patients with WND, but the physician treating the patient with suspicion of WND must always perform a detailed clinical diagnosis, taking the criteria established worldwide into account.

The p.L456 V polymorphism has been identified in different countries, but not its frequencies, making the comparison of our results impossible. In some cases, haplotypes are not constructed with the use of different SNPs determined in their studies and thus do not take advantage of the opportunity to broaden the molecular diagnosis. Even when new mutations are determined and techniques with microarrays are carried out in developing countries, it is necessary that genetic diseases are studied through molecular biology and that the search for polymorphisms is included to provide the service of molecular diagnosis through indirect methods in diseases that present with a considerable number of exons and few frequent mutations.

The establishment of a strategy for the molecular diagnosis of WND is being worked on in Cuba. Our work team has experience in identifying polymorphisms in exons 10 and 13 and in intron 9. With the polymorphisms that have already been detected, and now with the p.L456 V polymorphism in Cuban patients with the presumptive diagnosis of WND, haplotypes can be determined in the Cuban families with that disease, as well as molecular diagnosis through indirect methods. In addition to the detection of the p.L456 V polymorphism, different mutations have been reported in China, India, and Iran for establishing the molecular diagnosis of WND, making molecular diagnosis through indirect and direct methods possible, carrying out our strategies for the sake of improving the quality of life of the patients with WND.

In relation to the ethnic origin of the Cuban population, it is important to point out that the islands of the Caribbean, including Cuba, were the first to be inhabited by Mesoamericans and later by Amerindians, which some researchers have suggested came from Venezuela. It is estimated that the island had more than 100,000 inhabitants when the Spanish arrived and during the first 50 years of the Conquest, the population was reduced to about 5,000 individuals. The Spanish colonizers extinguished the Amerindian population and began to bring aborigines from North American and Mesoamerica to Cuba, as well as slaves from the West coast of Africa and black slaves from East Africa and Sub-Saharan Africa. Thus, the genetic composition of the Cuban population is basically a mixture of Caucasian Spaniards and black Africans. The Spanish immigration remained constant from the end of the fifteenth century to the first half of the twentieth century. The history of the ethnic miscenegaion that took place between those three original groups (Native Americans, Europeans, and Africans) for nearly five centuries has created the genetic structure of the current Cuban population. The average contribution of the genes of European, African, and Native American origin in the individuals studied was 72, 20, and 8%, respectively. Ethnicity was observed to play an important role in the distribution of the mutations in the ATP7B gene that are responsible for WND. Future study of the mutations and polymorphisms of the ATP7B gene in the American continent and the evaluation of the role of ethnicity in their presence, as well as in the susceptibility to disease, will be useful.

In conclusion, a molecular tool is available for introducing the molecular diagnosis in patients with WND in Cuba. The methodology can be used in other population with a genetic profile similar to that of Cuba.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Financial disclosure

No financial support was received in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.
Acknowledgments

The authors wish to thank the patients for participating in the present study, Lidice Reyes for performing the DNA extraction, The Public Health Ministry, Dr. Carlos Maragoto for his contributions, Georgios Loudianos for the delivery of the positive controls, and Dr. Carlos Castañeda for his contributions with respect to the clinical diagnosis of the disease.

References